Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Trichomonas vaginalis

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

Trichomonas vaginalis is a protozoan parasite characterized by its four flagella, primarily residing in the genital tract. It is recognized as the most prevalent non-viral sexually transmitted infection (STI), often presenting without symptoms, which can lead to significant health risks. These risks include an increased susceptibility to HIV infection and the potential development of cervical neoplasia. The CPT® Code 87808 pertains to the detection of this infectious agent through an immunoassay method that utilizes direct optical observation. This testing process typically involves collecting a clinical sample, frequently through vaginal swabbing. The sample is then subjected to a series of steps involving incubation with antibodies specifically designed to bind to Trichomonas vaginalis. Following this, the antigen-antibody complex is formed, and subsequent washing and probing steps are performed to quantify the presence of the parasite. The final measurement of Trichomonas vaginalis is determined by assessing the optical density, which correlates with the amount of the antigen present in the sample, providing a clear and direct method for diagnosis.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The procedure associated with CPT® Code 87808 is indicated for the detection of Trichomonas vaginalis in patients who may present with symptoms or are at risk for this infection. The following conditions warrant the use of this immunoassay:

  • Asymptomatic Infection Patients may be asymptomatic carriers of Trichomonas vaginalis, necessitating testing to identify the presence of the parasite and prevent potential complications.
  • Symptoms of Vaginitis Individuals presenting with symptoms such as vaginal discharge, itching, or irritation may require testing to confirm or rule out Trichomonas vaginalis as the causative agent.
  • Increased Risk for STIs Patients with a history of multiple sexual partners or other sexually transmitted infections may be tested for Trichomonas vaginalis due to the increased risk of co-infection.
  • Pregnancy Pregnant individuals may be screened for Trichomonas vaginalis to reduce the risk of complications such as preterm delivery and low birth weight.

2. Procedure

The procedure for CPT® Code 87808 involves several critical steps to ensure accurate detection of Trichomonas vaginalis. The following outlines the procedural steps:

  • Sample Collection A clinical sample is obtained, typically through a vaginal swab. This sample serves as the basis for the immunoassay test.
  • Preparation of the Microtiter Plate The collected sample is placed onto a microtiter plate that has been pre-coated with antibodies specific to Trichomonas vaginalis. This step is crucial for the subsequent binding of the antigen.
  • Incubation The sample is incubated, allowing the antigen from Trichomonas vaginalis to bind to the antibodies on the plate, forming an antibody-antigen complex.
  • Washing After incubation, the plate is washed to remove any unbound substances, ensuring that only the bound antigen remains for further analysis.
  • Probing with Enzyme-Conjugated Antibody The antigen in the complex is then probed by incubating with an enzyme-conjugated form of anti-Trichomonas vaginalis antibody, which binds to the antigen, enhancing the detection process.
  • Second Washing A second washing step is performed to eliminate any unbound enzyme-conjugated antibodies, further purifying the sample for accurate measurement.
  • Substrate Addition An enzyme substrate and chromogenic reagent are added to the plate. The enzyme reacts with the substrate, producing a color change that is proportional to the amount of Trichomonas vaginalis present.
  • Color Development and Measurement The incubation is halted by adding an acid, which also alters the color intensity produced by the chromogenic agent. The optical density is then measured, providing a quantifiable result that indicates the presence of Trichomonas vaginalis in the sample.

3. Post-Procedure

After the completion of the immunoassay procedure for CPT® Code 87808, the results are analyzed and interpreted. It is essential to communicate the findings to the patient and discuss any necessary follow-up actions, which may include treatment options if Trichomonas vaginalis is detected. Patients may also be advised on safe sexual practices to prevent reinfection or transmission. Additionally, healthcare providers should consider retesting in cases of persistent symptoms or if the patient has ongoing risk factors for STIs. Proper documentation of the results and any subsequent actions taken is crucial for maintaining accurate medical records and ensuring continuity of care.

Short Descr TRICHOMONAS ASSAY W/OPTIC
Medium Descr IAADIADOO TRICHOMONAS VAGINALIS
Long Descr Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Trichomonas vaginalis
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) Yes
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
QW Clia waived test
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
GC This service has been performed in part by a resident under the direction of a teaching physician
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
XS Separate structure, a service that is distinct because it was performed on a separate organ/structure
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
Date
Action
Notes
2022-01-01 Changed First appearance of change in codebook.
2021-01-01 Changed First appearance of change in CPT® Code Set.
2020-10-06 Changed Code description changed.
2007-01-01 Added First appearance in code book in 2007.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"